Aldehyde modification of peptide immunogen enhances protein-reactive antibody response to toxic shock syndrome toxin-1

Journal of Peptide Science

Volumn 12, Issue 12, 2006, Pages 843-849

  Bavoso, Alfonso ^a   Ostuni, Angela ^a   De Vendel, Jolanda ^a   Pollaro, Francesco ^c   Armentano, Francesca ^b   Knight, Thomas ^b   Makker, Sudesh ^b   Tramontano, Alfonso ^b  

^a UNIVERSITY OF BASILICATA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Igtech   (Italy)

Author keywords

Adjuvant; Aldehyde; Amadori reaction; Innate immunity; Peptide vaccine

Indexed keywords

ALDEHYDE DERIVATIVE; ALUMINUM POTASSIUM SULFATE; ANTIGEN; ANTITOXIN; CARBONYL DERIVATIVE; CARRIER PROTEIN; IMMUNOLOGICAL ADJUVANT; PEPTIDE VACCINE; TOXIC SHOCK SYNDROME TOXIN 1;

AMADORI REARRANGEMENT; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL ASSAY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG CONFORMATION; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPHARMACOLOGY; IMMUNOREACTIVITY; INNATE IMMUNITY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; RABBIT; TOXIC SHOCK SYNDROME; TOXICOKINETICS; VACCINE PRODUCTION; WESTERN BLOTTING;

ALDEHYDES; AMINO ACID SEQUENCE; ANIMALS; BACTERIAL TOXINS; BLOTTING, WESTERN; CELL PROLIFERATION; CIRCULAR DICHROISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; IMMUNE SERA; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDES; RABBITS; STAPHYLOCOCCUS AUREUS;

ORYCTOLAGUS CUNICULUS;

EID: 33845611895     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.821     Document Type: Article

References (32)

1. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect. Dis. 2002; 2(7): 425-431.
2. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L. Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur. J. Immunol. 2004; 34(11): 3102-3114.
3. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, Thomas A, Druilhe P. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 1997; 27(5): 1242-1253.
4. Thiele GM. Tuma DJ, Willis MS, Miller JA, McDonald TL, Sorrell MF, Klassen LW. Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant. Alcohol.: Clin. Exp. Res. 1998; 22(8): 1731-1739.
5. Allison ME, Fearon DT. Enhanced immunogenicity of aldehyde-bearing antigens: a possible link between innate and adaptive immunity. Eur. J. Immunol. 2000; 30(10): 2881-2887.
6. Horiuchi S, Murakami M, Takata K, Morino Y. Scavenger receptor for aldehyde-modified proteins. J. Biol. Chem. 1986; 261(11): 4962-4966.
7. Johnson WJ, Pizzo SV, Imber MJ, Adams DO. Receptors for maleylated proteins regulate secretion of neutral proteases by murine macrophages. Science 1982; 218(4572): 574-576.
8. Willis MS, Thiele GM, Tuma DJ, Klassen LW. T cell proliferative responses to malondialdehyde-acetaldehyde haptenated protein are scavenger receptor mediated. Int. Immunopharmacol. 2003; 3(10-11): 1381-1399.
9. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur. J. Immunol. 2000; 30(6): 1714-1723.
10. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit. Rev. Microbiol. 1990; 17(4): 251-272.
11. Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet 1981; 1(8228): 1017-1021.
12. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342(8884): 1385-1388.
13. Leung DY, Harbeck R, Bina P, Reiser RF, Yang E, Norris DA, Hanifin JM, Sampson HA. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J. Clin. Invest. 1993: 92(3): 1374-1380.
14. Takahashi N, Nishida H, Kato H, Imanishi K, Sakata Y, Uchiyama T. Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period. Lancet 1998; 351(9116): 1614-1619.
15. Abdelnour A, Bremell T, Holmdahl R, Tarkowski A. Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci. Eur. J. Immunol. 1994; 24(5): 1161-1166.
16. Hayakawa Y, Akagi M, Hayashi M, Shimano T, Komae H, Funaki O, Kaidoh T, Takeuchi S. Antibody response to toxic shock syndrome toxin-1 of Staphylococcus aureus in dairy cows. Vet. Microbiol. 2000; 72(3-4): 321-327.
17. Bonventre PF, Linnemann C, Weckbach LS, Staneck JL, Buncher CR, Vigdorth E, Ritz H, Archer D. Smith B. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J. Infect. Dis. 1984; 150(5): 662-666.
18. Stolz SJ, Davis JP, Vergeront JM, Crass BA, Chesney PJ, Wand PJ, Bergdoll MS. Development of serum antibody to toxic shock toxin among individuals with toxic shock syndrome in Wisconsin. J. Infect. Dis. 1985; 151(5): 883-889.
19. Bonventre PF, Heeg H, Cullen C, Lian CJ. Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect. Immun. 1993; 61(3): 793-799.
20. Bonventre PF, Heeg H, Edwards CK 3rd, Cullen CM. A mutation at histidine residue 135 of toxic shock syndrome tolin yields an immunogenic protein with minimal toxicity. Infect. Immun. 1995; 63(2): 509-515.
21. Gampfer J, Thon V, Guile H, Wolf HM, Eibl MM. Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome. Vaccine 2002; 20(9-10): 1354-1364.
22. Gampfer JM, Samstag A, Waclavicek M, Wolf HM, Eibl MM, Gulle H. Epitope mapping of neutralizing TSST-1 specific antibodies induced by immunization with toxin or toxoids. Vaccine 2002; 20(31-32): 3675-3684.
23. Rubinchik E, Chow AW. Recombinant expression and neutralizing activity of an MHC class II binding epitope of toxic shock syndrome toxin-1. Vaccine 2000; 18(21): 2312-2320.
24. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994: 233: 346-357.
25. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 2000: 408(6813): 740-745.
26. Koradi R, Billeter M, Wuthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graphics 1996; 14(1): 51-5, 29-32.
27. Papageorgiou AC, Quirm CP, Beer D, Brehm RD, Tranter HS, Bonventre PF, Acharya KR. Crystal structure of a biologically inactive mutant of toxic shock syndrome toxin-1 at 2.5 A resolution. Protein Sci. 1996; 5(8): 1737-1741.
28. Papageorgiou AC, Brehm RD, Leonidas DD, Tranter HS, Acharya KR. The refined crystal structure of toxic shock syndrome toxin-1 at 2.07 A resolution. J. Mol. Biol. 1996: 260(4): 553- 569.
29. Hurley JM, Shimonkevitz R, Hanagan A, Enney K, Boen E, Malmstrom S, Kotzin BL, Matsumura M. Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1. J. Exp. Med. 1995; 181(6): 2229-2235.
30. Kum WW, Wood JA, Chow AW. A mutation at glycine residue 31 of toxic shock syndrome toxin-1 defines a functional site critical for major histocompatibility complex class II binding and superantigenic activity. J. Infect. Dis. 1996; 174(6): 1261-1270.
31. Pang LT, Kum WW, Chow AW. Inhibition of staphylococcal enterotoxin B-induced lymphocyte proliferation and tumor necrosis factor alpha secretion by MAb5, an anti-toxic shock syndrome toxin 1 monoclonal antibody. Infect. Immun. 2000: 68(6): 3261-3268.
32. Earhart CA, Mitchell DT, Murray DL, Pinheiro DM, Matsumura M, Schlievert PM, Ohlendorf DH. Structures of five mutants of toxic shock syndrome toxin-1 with reduced biological activity. Biochemistry 1998; 37(20): 7194-7202.